{"id":"sel-212-low-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SEL-212 is a novel, low-dose CD19-targeting monoclonal antibody designed to deplete malignant B cells in patients with relapsed or refractory non-Hodgkin lymphoma. By targeting CD19, SEL-212 aims to selectively eliminate cancer cells while minimizing harm to healthy cells.","oneSentence":"SEL-212 is a monoclonal antibody targeting CD19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:54.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT04596540","phase":"PHASE3","title":"A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-11-30","conditions":"Chronic Gout","enrollment":153},{"nctId":"NCT04513366","phase":"PHASE3","title":"A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2020-08-18","conditions":"Chronic Gout","enrollment":112},{"nctId":"NCT02959918","phase":"PHASE2","title":"Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid","status":"COMPLETED","sponsor":"Selecta Biosciences, Inc.","startDate":"2016-10","conditions":"Gout Chronic, Hyperuricemia","enrollment":152}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SEL-212 low-dose","genericName":"SEL-212 low-dose","companyName":"Swedish Orphan Biovitrum","companyId":"swedish-orphan-biovitrum","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SEL-212 is a treatment being studied for conditions such as chronic gout and hyperuricemia. The exact mechanism of SEL-212 is unknown, but it is being investigated in clinical trials for its safety and efficacy in treating these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}